Interim report of the UKCLL02 Trial: a phase II study of subcutaneous alemtuzumab plus fludarabine in patients with fludarabine refractory CLL (on behalf of the NCRI CLL Trials Sub-Group)

被引：0
|
作者：
Sayala, HA
Moreton, P
Jones, RA
Rawstron, AC
O'Connor, SJ
Evans, P
Carter, A
Dearden, C
Matutes, E
Pettitt, AR
Kennedy, DB
Hillmen, P
机构：
[1] Leeds Gen Infirm, HMDS, Leeds, W Yorkshire, England
[2] Royal Liverpool Univ Hosp, Dept Haematol, Liverpool, Merseyside, England
[3] Inst Canc Res, Haematooncol Dept, London SW3 6JB, England
[4] Leicester Royal Infirm, Dept Haematol, Leicester, Leics, England
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2006年 / 133卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：3 / 3
页数：1
相关论文
共 50 条
  • [31] Fludarabine plus cyclophosphamide (FC) and dose intensified chlorambucil (DIC) for the treatment of chronic lymphocytic leukemia (CLL):: Results of two phase II studies (CLL2-protocol) of the german cll study group (GCLLSG).
    Hallek, M
    Wilhelm, M
    Emmerich, B
    Döhner, H
    Fostitsch, HP
    Sezer, O
    Herold, M
    Knauf, W
    Busch, R
    Schmitt, B
    Wendtner, CM
    Kuse, R
    Freund, M
    Franke, A
    Schriever, F
    Nerl, C
    Thiel, E
    Hiddemann, W
    Brittinger, G
    BLOOD, 1999, 94 (10) : 313A - 313A
  • [32] Cyclophosphamide, Adriamycin, Vincristine and Prednisone Plus Rituximab (CHOP-R) in Fludarabine (F) Refractory Chronic Lymphocytic Leukemia (CLL) or CLL with Autoimmune Cytopenia (AIC) or Richter's Transformation (RT): Final Analysis of a Phase II Study of the German CLL Study Group
    Jenke, Petra
    Eichhorst, Barbara
    Busch, Raymonde
    Anheier, Nadine
    Duehrsen, Ulrich
    Duerig, Jan
    Dreyling, Martin H.
    Bergmann, Manuela
    Goebeler, Maria Elisabeth
    Hurts, Hans Juergen
    Stauch, Martina Beate
    Stilgenbauer, Stephan
    Doehner, Hartmut
    Fink, Anna-Maria
    Fischer, Kirsten
    Wendtner, Clemens-Martin
    Hallek, Michael
    BLOOD, 2011, 118 (21) : 1233 - 1234
  • [33] Ofatumumab (HuMax-CD20), a Novel CD20 Monoclonal Antibody, Is An Active Treatment for Patients with CLL Refractory to Both Fludarabine and Alemtuzumab or Bulky Fludarabine-Refractory Disease: Results from the Planned Interim Analysis of An International Pivotal Trial
    Osterborg, Anders
    Kipps, Thomas J.
    Mayer, Jiri
    Stilgenbauer, Stephan
    Williams, Catherine D.
    Hellmen, Andrzej
    Robak, Tadeusz
    Furman, Richard R.
    Hillmen, Peter
    Trneny, Marek
    Dyer, Martin J. S.
    Padmanabhan, Swaminathan
    Kozak, Tomas
    Chan, Geoffrey
    Davis, Randy L.
    Losic, Nedjad
    Russell, Charlotte A.
    Piotrowska, Magdalena
    Wilms, Joris
    Wierda, William G.
    BLOOD, 2008, 112 (11) : 126 - 127
  • [34] TPLL-1 protocol of the German CLL study group (GCLLSG) - A prospective phase II trial of fludarabine phosphate, mitoxantrone and cyclophosphamide (FMC) followed by alemtuzumab consolidation in T-PLL
    Hopfinger, Georg
    Busch, Raymond
    Barbara, Eichhorst
    Paula, Cramer
    Gabriele, Kandler
    Gunther, Fingerle-Rowson
    Anna-Maria, Fink
    Stephan, Stilgenbauer
    Michael, Hallek
    BLOOD, 2007, 110 (11) : 607A - 607A
  • [35] Subcutaneous Alemtuzumab in Fludarabine-Refractory Chronic Lymphocytic Leukemia: Clinical Results and Prognostic Marker Analyses From the CLL2H Study of the German Chronic Lymphocytic Leukemia Study Group
    Stilgenbauer, Stephan
    Zenz, Thorsten
    Winkler, Dirk
    Buehler, Andreas
    Schlenk, Richard F.
    Groner, Silja
    Busch, Raymonde
    Hensel, Manfred
    Duehrsen, Ulrich
    Finke, Juergen
    Dreger, Peter
    Jaeger, Ulrich
    Lengfelder, Eva
    Hohloch, Karin
    Soeling, Ulrike
    Schlag, Rudolf
    Kneba, Michael
    Hallek, Michael
    Doehner, Hartmut
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (24) : 3994 - 4001
  • [36] RITUXIMAB MAINTENANCE AFTER COMBINED FCR IN PREVIOUSLY UNTREATED PATIENTS WITH ACTIVE B-CELL CLL: INTERIM ANALYSIS OF AN ONGOING PHASE II MULTICENTER TRIAL ON BEHALF OF THE SPANISH CLL STUDY GROUP (GELLC)
    Garcia-Marco, J.
    Lopez, J.
    Gonzalez, E.
    Giraldo, P.
    Conde, E.
    De La Serna, J.
    Gonzalez, M.
    Carbonell, F.
    Garcia-Vela, J.
    ANNALS OF ONCOLOGY, 2011, 22 : 172 - 172
  • [37] First line therapy of patients (pts) with advanced chronic lymphocytic leukemia (CLL) older than 65 years with fludarabine versus chlorambucil: Interim analysis of a phase III study of the German CLL Study Group (GCLLSG).
    Schmitt, BF
    Kneba, M
    Ritgen, M
    Stauch, M
    Emmerich, B
    Bergmann, M
    Busch, R
    Wendtner, CM
    Hallek, M
    BLOOD, 2002, 100 (11) : 387A - 387A
  • [38] T-PLL-1 protocol of the German CLL study group (GCLLSG) - A prospective phase II trial of fludarabine phosphate, mitoxantrone and cyclophosphamide (FMC) followed by alemtuzumab consolidation in T-PLL.
    Hopfinger, G
    Busch, R
    Eichhorst, B
    Kandler, G
    Wendtner, C
    Hallek, M
    BLOOD, 2005, 106 (11) : 602A - 603A
  • [39] A phase II trial of fludarabine followed by alemtuzumab (Campath-1H) in previously untreated chronic lymphocytic leukemia (CLL) patients with active disease: Cancer and Leukemia Group B (CALGB) study 19901.
    Rai, KR
    Byrd, JC
    Peterson, BL
    Larson, RA
    BLOOD, 2002, 100 (11) : 205A - 206A
  • [40] International Phase III Study of Chlorambucil Versus Fludarabine As Initial Therapy for Waldenstrom's Macroglobulinemia and Related Disorders: Results in 414 Patients on Behalf of FCG CLL/WM, GOELAMS, GELA, NCRI, ALLG
    Leblond, Veronique
    Lejeune, Julie
    Tournilhac, Olivier
    Morel, Pierre
    Dilhuydy, Marie Sarah
    Dartigeas, Caroline
    Malphette, Marion
    Royer, Bruno
    Seymour, John F.
    Chevret, Sylvie
    Johnson, Steve
    Owen, Roger G.
    BLOOD, 2011, 118 (21) : 351 - 352
12345